Weak Growth To Continue

BMI View: Despite stronger than expected pharmaceutical sales during the first nine months of 2010, BMI's projection that Estonia will post only marginal growth in 2010 has been confirmed. The key drawback to investment in Estonia's drug market is its small size and weak outlook for growth. Furthermore, the government has recently taken a more proactive stance in relation to the promotion of generics, which will have a bearing on the market's development, especially in light of the challenging economic conditions.

To read the full article, please choose one of the following options: